Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Feuring

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Der Internist|March 31, 1999
[Important differences in metabolism of CSE inhibitors]M Feuring, M Wehling
Der Internist|April 20, 2006
[Stem cell therapy]M Feuring-Buske, W Hiddemann
International Journal of Clinical Pharmacology and Therapeutics|October 4, 2011
Lepirudin dose-dependently increases thrombelastography parameters at therapeutic plasma concentrations as measured with ROTEM® - a pilot studyM Feuring, M Wehling, A Schultz
The Journal of International Medical Research|February 1, 2012
Long-term, high intake of vitamin C decreases size and increases quantity of liver mitochondria in Guinea-pigsM Feuring, A Schultz, K Hersemeyer
Der Internist|May 8, 2000
[Effect of genetic factors and illnesses on drug efficacy]M Feuring, M Wehling, E Falkenstein
Blood|June 5, 2001
Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemiaM Feuring-Buske, D E Hogge
Der Internist|April 1, 2006
[Stem cell therapy. Biology of hematopoietic stem cells]C Buske, H Glimm, M Feuring-Buske
Der Internist|January 15, 2003
[Pathogenesis and biology of leukemias]M Feuring-Buske, W Hiddemann, C Buske
Cell Cycle (Georgetown, Tex.)|November 19, 2005
AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemiaF Kuchenbauer, M Feuring-Buske, C Buske
Platelets|September 3, 2010
Coagulation status in coronary artery disease patients with type II diabetes mellitus compared with non-diabetic coronary artery disease patients using the PFA-100® and ROTEM®M Feuring, M Wehling, H Burkhardt, et al.
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Der Internist|March 31, 1999
[Important differences in metabolism of CSE inhibitors]M Feuring, M Wehling
Der Internist|April 20, 2006
[Stem cell therapy]M Feuring-Buske, W Hiddemann
International Journal of Clinical Pharmacology and Therapeutics|October 4, 2011
Lepirudin dose-dependently increases thrombelastography parameters at therapeutic plasma concentrations as measured with ROTEM® - a pilot studyM Feuring, M Wehling, A Schultz
The Journal of International Medical Research|February 1, 2012
Long-term, high intake of vitamin C decreases size and increases quantity of liver mitochondria in Guinea-pigsM Feuring, A Schultz, K Hersemeyer
Der Internist|May 8, 2000
[Effect of genetic factors and illnesses on drug efficacy]M Feuring, M Wehling, E Falkenstein
Blood|June 5, 2001
Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemiaM Feuring-Buske, D E Hogge
Der Internist|April 1, 2006
[Stem cell therapy. Biology of hematopoietic stem cells]C Buske, H Glimm, M Feuring-Buske
Der Internist|January 15, 2003
[Pathogenesis and biology of leukemias]M Feuring-Buske, W Hiddemann, C Buske
Cell Cycle (Georgetown, Tex.)|November 19, 2005
AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemiaF Kuchenbauer, M Feuring-Buske, C Buske
Platelets|September 3, 2010
Coagulation status in coronary artery disease patients with type II diabetes mellitus compared with non-diabetic coronary artery disease patients using the PFA-100® and ROTEM®M Feuring, M Wehling, H Burkhardt, et al.
Pageof 8